Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.

Driven by Science

Rapid, efficient, cost-effective approach

Our expert team is skilled at identifying promising drug candidates and advancing them through all stages of drug development.

More...

Focused on Life

Developing novel small molecule drugs for serious diseases

We aim to transform the treatment of neurologic diseases and cancer and offer hope to patients and their caregivers.

More...

Dimebon (latrepirdine)

Late-stage investigational drug for Alzheimer’s and Huntington diseases

For patients and caregivers struggling with these debilitating neurodegenerative diseases, dimebon may offer new hope to improve their lives.

More...

MDV3100

First triple-acting, oral anti-androgen drug candidate in clinical development to treat advanced prostate cancer

We are committed to advancing the development of MDV3100 as quickly as possible for patients with advanced prostate cancer, who have few treatment options and a poor prognosis.

More...

News & Recent Releases

Wednesday, March 3, 2010

Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Tuesday, March 2, 2010

Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease

Careers

No current open positions